Last updated: February 24, 2026
What is NDC 64950-0381?
NDC 64950-0381 corresponds to Tavneos (avacopan), developed byChemoCentryx. It is an oral, selective C5a receptor inhibitor approved by the FDA in October 2021 for treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), both forms of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Market Size and Demand Drivers
Patient Population
-
Prevalence and Incidence
- GPA and MPA are rare vasculitides with combined prevalence estimates at 3-4 cases per 100,000 in the U.S.
- Approximately 6,000-9,000 new cases annually in the U.S. (based on 2017 data [1]).
-
Treatment Landscape
- Traditional therapy involves corticosteroids, cyclophosphamide, rituximab.
- Tavneos offers a non-immunosuppressive oral alternative.
Market Penetration
- Initial adoption limited by competition from established therapies.
- Key drivers include:
- Physician acceptance due to safety profile.
- Insurance coverage and pricing strategies.
- Patient preferences for oral over injectable treatments.
Competitive Landscape
| Drug |
Mechanism |
Approval Year |
Market Share (2022) |
Key Advantages |
| Rituximab |
Anti-CD20 monoclonal antibody |
2011 |
60-70% |
Proven efficacy, established use |
| Cyclophosphamide |
Alkylating agent |
1950s |
Remaining share |
Cost-effective, longstanding role |
| Tavneos (avacopan) |
C5a receptor inhibitor |
2021 |
Emerging |
Oral administration, targeted |
Market Forecasts
- Market size estimates project annual sales reaching $200-300 million within 5 years post-launch in the U.S., considering:
- Competition from current standards.
- Growing diagnosis rates.
- Expanded indications (e.g., GPA/MPA in maintenance or other vasculitides).
Pricing and Reimbursement
-
Initial Pricing
- List price set at approximately $56,000 - $60,000 per year per patient (based on initial estimates [2]).
-
Cost Comparison
- Less expensive than rituximab infusions (~$30,000 - $50,000 per dose, administration included [3]).
- Potential for price reductions as market expands and biosimilars emerge.
-
Reimbursement
- Coverage primarily through Medicare and private insurers.
- Reimbursement levels influence uptake.
Price Projections
| Year |
Estimated Annual Price |
Projected Sales |
Key Factors |
| 2023 |
$56,000 |
$50-100 million |
Market entry, initial physician adoption |
| 2024 |
$55,000 |
$100-150 million |
Increased awareness, insurance coverage |
| 2025 |
$50,000-$55,000 |
$150-200 million |
Competition intensifies or market expansion |
Risks and Opportunities
-
Risks
- Slow adoption due to conservative prescribing.
- Pricing pressures from payers.
- Competition from generics or biosimilars, like rituximab biosimilars (approved in 2020s).
-
Opportunities
- Expansion into other indications.
- Line extensions for maintenance therapy.
- Geographic expansion outside the U.S.
Regulatory and Policy Influences
- Pricing policies may extend or restrict market access.
- Orphan drug status (if applicable) could provide market exclusivity, impacting price strategies.
- Partnerships and collaborations might influence market penetration and pricing negotiations.
Key Takeaways
- NDC 64950-0381 (Tavneos) targets a niche but growing market driven by rare disease prevalence.
- Initial pricing set at ~$56,000/year, with projections to sustain sales in $150-200 million range annually by 2025.
- Market growth hinges on physician acceptance, insurance reimbursement, and competition from existing therapies.
- Opportunities exist for broader indications and geographic expansion, but risks include payer resistance and biosimilar competition.
FAQs
1. How does Tavneos compare to rituximab in terms of price?
Tavneos lists at approximately $56,000 annually, whereas rituximab costs vary but can reach $30,000-$50,000 per infusion, with total treatment costs often higher due to infusion and monitoring.
2. What are the main barriers to market penetration for Tavneos?
Physician familiarity with existing therapies, insurance reimbursement processes, and competition from established drugs like rituximab pose primary barriers.
3. Could biosimilars impact Tavneos’s pricing?
While biosimilars are more common for monoclonal antibodies, biosdeclare avacopan’s market could pressure prices if generics emerge and gain approval.
4. Are there regulatory hurdles affecting market expansion?
Yes. Expansion into additional indications requires clinical trials, and regulatory policies on orphan or rare disease drugs can influence market exclusivity and pricing.
5. What is the outlook for international markets?
Potential exists for expansion into Europe and Asia, where vasculitis treatments are less entrenched, but regulatory approval timelines and reimbursement conditions vary.
References
- Watts, R., et al. (2017). European Vasculitis Study Group (EUVAS). Prevalence and incidence of vasculitis. Rheumatology, 56(5), 763-771.
- ChemoCentryx. (2022). Tavneos (avacopan) pricing and reimbursement information. Manufacturer disclosure.
- U.S. Bureau of Labor Statistics. (2022). Healthcare costs for infusion therapies.
- FDA. (2021). Tavneos (avacopan) approval announcement.
Disclaimer: All projections are estimates based on current market data and may vary due to changes in healthcare policies, market dynamics, and competitive actions.
